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Background: TAR DNA-binding protein 43 (TDP-43) is a protein that is involved in the pathology of Amyotrophic
Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). In patients with these neurodegenerative
diseases, TDP-43 does not remain in its normal nuclear location, but instead forms insoluble aggregates in both the
nucleus and cytoplasm of affected neurons.
Results: We used high density peptide array analysis to identify regions in TDP-43 that are bound by TDP-43 itself
and designed candidate peptides that might be able to reduce TDP-43 aggregation. We found that two of the
synthetic peptides identified with this approach could effectively inhibit the formation of TDP-43 protein
aggregates in a concentration-dependent manner in HeLa cells in which a mutated human TDP-43 gene was
overexpressed. However, despite reducing aggregation, these peptides did not reduce or prevent cell death. Similar
results were observed in HeLa cells treated with arsenite. Again we found reduced aggregation, in this case of wild
type TDP-43, but no difference in cell death.
Conclusions: Our results suggest that TDP-43 aggregation is associated with the cell death process rather than
being a direct cause.
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Recent evidence links TDP-43 pathology to at least two
forms of neurodegeneration that had heretofore been
thought to be quite separate. FTLD is the second most
common type of early-onset neurodegenerative dementia
after Alzheimer’s disease, and ALS is the most common
adult-onset progressive motor neuron disease (MND).
The TAR DNA binding protein 43 (TDP-43) has been
found to be the major protein constituent of the intracel-
lular aggregated inclusions in both FTLD with ubiquitin-
positive inclusions (FTLD-U) and ALS [1,2].
TDP-43 is a 414 amino acid protein encoded by the
TARDBP gene on chromosome 1. It was originally iden-
tified as a transcriptional repressor of the human im-
munodeficiency virus type 1 (HIV-1) gene [3,4] and the
mammalian gene SP-10 [5]. TDP-43 normally is found
in the nucleus where it regulates RNA splicing, mRNA
stability and microRNA processing [6-9], but TDP-43 in* Correspondence: cynader@brain.ubc.ca
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reproduction in any medium, provided the orpathological inclusions is generally hyperphosphorylated,
ubiquitinated [10], and cleaved to 35 and 25 kDa species
[11]. The pathological aggregates are frequently found in
the cytoplasm rather than at TDP-43’s normal nuclear
location [1,2,12].
The mechanism through which TDP-43 is involved in
neuronal death and degeneration remains unclear. One
of the best characterized pathological features of TDP-
43 proteinopathies is the cytoplasmic inclusions of TDP-
43 aggregates. As with other protein misfolding diseases,
TDP-43 mediated toxicity may result from a toxic gain
of function associated with its aggregation. Johnson and
colleagues have established a yeast model involving over-
expressed full-length human TDP-43 or various TDP-43
truncation products [13]. They found that express-
ing a truncated form of TDP-43 containing both the
C-terminal and RRM2 promoted aggregation. Only the
aggregated form of TDP-43 induced toxicity to yeast
cells. This suggested that TDP-43 misfolding and aggre-
gation might be an important cause of cell death in neu-
rodegenerative diseases. Another group supported this
conclusion in human cell models [14]. The 25 kDaThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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caspase-3 cleavage product [15], was overexpressed in
HEK293 and differentiated M17 neuroblastoma cells. The
25 kDa fragment of TDP-43 formed cytoplasmic inclu-
sions, induced cell toxicity, but did not disturb endo-
genous TDP-43 functions. Moreover, it was found that
aggregation of mitochondria seems to be a common fea-
ture when overexpressing TDP-43 in transgenic mice
[16,17]. All these data point to the toxicity of TDP-43 ag-
gregates, or of the processes by which they form.
To further elucidate the links between TDP-43 aggre-
gation and disease mechanisms, we used two different
models. The first was an aggregation model pioneered
by Nonaka and colleagues [18]. They found that a mu-
tant TDP-43 lacking residues 187–192 formed intra-
nuclear dot-like inclusions when expressed in SY5Y
cells. A second model relied in recent findings that ar-
senite treatment can induce aggregation of wild-type
TDP-43. When HeLa cells are treated with arsenite, an
established stress granule (SG) inducer [19,20], TDP-43
aggregation occurs in the cytoplasm. Arsenite reacts
with oxygen, induces oxidative stress and then activates
HRI (Heme-regulated inhibitor), whose expression is re-
quired for SG formation [21]. SGs are cytoplasmic sites of
stalled mRNA pre-initiation complexes induced by mul-
tiple stressors. Recent data have shown that SGs partici-
pate in the process of TDP-43 accumulation [22,23]. With
these two models in hand, we asked whether selectively
blocking aggregation would affect cellular toxicity. Inhib-
ition of TDP-43 aggregation is considered to be a major
potential therapeutic avenue for ALS and FTLD-U. Simi-
lar to the situation for other neurodegenerative diseases,
potential tools include antibodies, molecular chaperones,
chemical compounds and synthetic peptides. The strategy
we used to design aggregation blockers was to identify
and synthesize TDP-43 fragments that bind with full
length TDP-43 protein. Our findings indicate that the syn-
thetic peptides reduced the formation of TDP-43 aggre-
gates in both models used, but did not reduce or prevent
cell death.
Results
TDP-43 protein binds with selected TDP-43 derived
peptides on the membrane
The protein array described in the Methods section was
used to identify candidate binding regions at which TDP-
43 might interact with itself. Given the nature of the
overlapping sequences associated with each neighboring
peptide (frame shift of 2 aa), only positive spots in a series
were considered as possible binding sites. Five separate
and robust binding regions were found on the TDP-43
peptide array after incubating the membrane with recom-
binant TDP-43 protein followed by visualization of an
antibody against TDP-43 (Figure 1). This result suggeststhat the five regions may potentially be involved in self
binding or interaction of TDP-43. Based on these pos-
sible interaction domains, five peptide candidates, called
Peptide A-E, were designed and synthesized. The pep-
tides were derived from the sequence of full length
TDP-43. The overlapping amino acids are the possible
binding domains and are indicated in Figure 1. The dis-
tribution of five peptides is shown on the schematic of
TDP-43 structure.
The synthetic peptides were able to block the interaction
between recombinant TDP-43 protein and its peptide
array membrane
To verify whether the five regions of TDP-43 identified
through the array assay are actually involved in self
binding of the protein, the five peptides indicated in
Figure 1 were synthesized and tested for their ability to
inhibit the binding between full length TDP-43 and the
TDP-43 peptide array (Figure 2). A scrambled peptide
TC was designed as a control. Peptide TC has the same
length, net charge, and number of hydrophilic and
hydrophobic amino acids as Peptide C. It has a random
order and substitutions with the structure disrupting
amino acids of original peptide. The results showed that
a mixture of the five peptides blocked the interaction
between TDP-43 and its peptide array (decrease by
76.05% ± 3.46% compared to control) (Figure 2A, B).
However, the control peptide TC was not able to block
the interaction (Figure 2C).
Synthetic peptides inhibit aggregation of overexpressed
mutated TDP-43 in HeLa cells
To examine whether the peptides blocking interaction of
recombinant TDP-43 protein with the peptide array could
also inhibit TDP-43 aggregation in cells, a construct ex-
pressing a mutant TDP-43 lacking residues 187–192 [18]
was transfected into HeLa cells. A construct expressing
wild-type TDP-43 was used as a control. Immunohisto-
chemical analysis was performed 48 hours after trans-
fection. As shown in Figure 3, while all cells express
wild-type TDP-43, only cells transfected with mutant
TDP-43 showed TDP-43 aggregates (18.40% ± 0.62%),
demonstrated by punctate staining in the nuclei.
To investigate whether the synthetic peptides could in-
hibit the aggregation of mutant TDP-43, N-terminally
TAT conjugated peptides A, B, C, D, E and/or TC were
added to the cell culture medium after transfection. The
peptides were added either individually or combined to-
gether in various ways (peptide A-E mixture, or peptide
B and C mixture). The TAT peptide has been used to
deliver large molecules and small particles across both
the plasma membrane and the nuclear membrane [24].
The number of mutant TDP-43 inclusions decreased in
cells transduced with the peptides (Figures 3 and 4).
Figure 1 Identification of peptide candidates that may block TDP-43 binding to itself using the high density peptide array. TDP-43
protein associates with TDP-43 membrane at specific regions. Control, binding of the antibody only to the TDP-43 membrane; TDP-43, The
TDP-43 membrane was incubated with TDP-43 protein (three repeats). The schematic representation shows the five peptide candidates labeled
on the membranes. The peptides were designed based on the identified regions of the membrane to which purified TDP-43 bound.
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ive at reducing aggregation than the other synthetic
peptides derived from TDP-43 or than the control TC
peptide. Compared to untreated cells, cells with TDP-
43 aggregates were reduced by 52% ± 8.85% (p < 0.01),
72% ± 2.33% (p < 0.01), and 91% ± 3.56% (p < 0.01) after
treatment with Peptide B (20 μM), Peptide C (20 μM)
and a Peptide B and C mixture (20 μM), respectively
(Figure 4A). In addition, the peptides blocked aggrega-
tion in a concentration-dependent manner (Figure 4B).
Peptides A, D, E or the scrambled control TC did not
show statistically significant effects (Figure 4A). Pep-
tides A-E applied to the untransfected cells had no ef-
fect on cell viability.
Synthetic peptides inhibit aggregation of endogenous
TDP-43 induced by arsenite stress in HeLa cells
To investigate whether our peptides could inhibit aggre-
gation of wild-type TDP-43 under stress conditions,
HeLa cells were treated with arsenite with or withoutaddition of synthetic peptides. After exposure to 0.5 μM
arsenite with or without 10 μM of the synthetic peptide
mixture (ABCDE) for 4 hours, the cell lysates were
sequentially extracted and separated into soluble and
insoluble proteins. The relative ratio of insoluble to
soluble TDP-43 was used as a measure of TDP-43 aggre-
gation propensity. After the treatment with arsenite,
soluble endogenous TDP-43 was transformed into pre-
dominantly insoluble protein and showed a significant
increased aggregation propensity (243.23 ± 22.97%) com-
pared with control cells without treatment (41.02 ±
24.02%) (Figure 5). When the synthetic peptides (Peptide
A-E mixture) were coincubated along with the arsenite,
the ratio of insoluble to soluble TDP-43 decreased to
109.13 ± 25.00%. Treatment with the scrambled peptide
did not lead to any reduction compared to non-treated
arsenite-stressed cells (221.57% ± 46.76%) (Figure 5).
These results show that our synthetic peptides can re-
duce the formation of insoluble wild-type TDP-43 under
stress conditions.
Figure 2 Validated peptide candidates that may block TDP-43
binding determined using a high density peptide array. The
peptide mixture inhibits the binding between TDP-43 protein and
the membrane. Membranes were incubated with A, TDP-43 protein;
B, TDP-43 protein and a mixture of the five candidate peptides;
C, TDP-43 protein and the scrambled peptide TC. The data show
that the five candidate peptides can effectively inhibit the binding
of TDP-43 to the TDP-43 membrane. The experiment was repeated
three times with similar results.
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To ask whether TDP-43 aggregation is the cause of cell
death, we used MTT and TUNEL assays to examine
cell viability in cells expressing the mutant TDP-43.
Overexpression of the mutant TDP-43 did indeed induce
significant cell death (64.60 ± 5.44% cell viability, p <
0.01) compared to untreated cells. Treatment with Pep-
tide B and C, which significantly reduced the aggrega-
tion, led to similar levels of cell viability (71.37% ± 3.30%,
p < 0.01) as was found in untreated and scrambled pep-
tide treated cells (68.90% ± 2.96%, p < 0.01) (Figure 6).
Similar results were observed in the cells in which
wild-type TDP-43 aggregation was reduced after treat-
ment with arsenite and synthetic peptides. Treatment
with arsenite induced significant HeLa cell death
(53.32 ± 8.13% cell viability, p < 0.01) compared to the
basal condition. Our synthetic peptides decreased in-
soluble TDP-43 but did not prevent cell death (55.10 ±
9.38% cell viability, p < 0.01) (Figure 7). These results
indicate that TDP-43 aggregation was associated withcell death, but inhibition of TDP-43 aggregation could
not rescue or prevent cell death.
To further elucidate the relationship between the cell
death and TDP-43 aggregation, the cells were triple-
labeled with TDP-43, GFP and the cell death marker,
TUNEL. The numbers of transfected cells, aggregation-
positive cells, or TUNEL-positive cells were counted by
a blinded independent investigator. We measured four
fields and 1000–1200 cells per microscope slide. We
found that almost all the cells with TDP-43 aggregation
that were untreated, Peptide B and C treated, or scram-
bled peptide (TC) treated showed TUNEL positive
signals. In addition, even though Peptides B and C com-
bined reduced TDP-43 aggregation, a much higher per-
centage of dead cells were observed in Peptides B and C
treated cells without aggregation (12.22% ± 0.75%) than
in scrambled peptide treated cells (5.95% ± 0.95%).
Finally, we also measured cell death in cells without
mutant TDP-43 overexpression but treated with the
peptides. Cell death percentage in the untransfected
cells of wild-type TDP-43, mutant TDP-43, mutant
TDP-43 plus peptides BC and mutant TDP-43 plus
scrambled peptide groups were 3.14% ± 0.56%, 2.28% ±
0.36%, 3.22% ± 0.35%, and 3.57% ± 0.39%, respectively
(Figure 8). There was no difference among all of these
groups, indicating that the peptides themselves were
noncytotoxic.
Discussion
Here we report the development of synthetic peptides that
can reduce the aggregation of mutant TDP-43 and can
prevent the formation of stress induced wild type TDP-43
inclusions in HeLa cell models. We were concerned about
“off-target” interactions of our peptides. We found no
other proteins sharing the same sequences of TDP-43 to
which peptides bind after searching the NCBI molecular
biology database. We therefore think that off-target inter-
actions may be less likely.
Our findings confirm an earlier report by Nonaka and
colleagues in SY5Y cells by showing that mutated TDP-43
(Δ187-192) can induce TDP-43 aggregation and cell death
in HeLa cells [18]. However, although many TDP-43 mu-
tations have been found, the majority of ALS and FTLD-U
cases have no known TDP-43 mutations and instead, it is
wild-type TDP-43 that aggregates in these conditions [25].
Accordingly, we tested our peptides on a second model in
HeLa cells in which the formation of insoluble endogen-
ous TDP-43 aggregates was induced by oxidative stressor
arsenite [26]. Increased TDP-43 aggregation was observed
and quantified using immunocytochemical and biochem-
ical methods (separation of soluble and insoluble protein).
Importantly, while the peptides reduced both mutant
TDP-43 and endogenous TDP-43 aggregation induced by
stress in a concentration-dependent manner, they did not
Figure 3 Expression of mutated TDP-43 (deletion of 187–192 AA) results in the formation of inclusions. Immunofluorescent detection of
TDP-43 in HeLa cells with anti-TDP-43 antibody (left panel, green), nuclear staining by Hoechst (right panel, blue). A: untransfected HeLa cells;
B: HeLa cells examined 48 h post transfection with mutated TDP-43; C and D: HeLa cells examined 48 h post transfection with mutated TDP-43,
followed by addition of the mixture of five peptides (10 μM) (C) or the scrambled peptide TC (10 μM) (D) to the culture medium. The peptides
effectively inhibited aggregation of TDP-43 in HeLa cells. The experiment was repeated three times with similar results.
Liu et al. Acta Neuropathologica Communications 2013, 1:49 Page 5 of 11
http://www.actaneurocomms.org/content/1/1/49prevent or reduce the cytotoxicity caused by overexpression
of the mutant TDP-43. These data suggest that while TDP-
43 aggregation is associated with the process of cytotox-
icity, it is not the cause of cell death in our model.
Our results indicating that aggregation may not be the
causative factor for cytotoxicity in cells expressing mu-
tant TDP-43, appear consistent with other emerging evi-
dence that aggregation is not necessarily the cause of
cellular toxicity. Previous work from our lab [27] showed
that knockdown of progranulin in mouse cortical neu-
rons induced TDP-43 translocation from nucleus to the
cytoplasm and resulted in enhanced vulnerability to sev-
eral stressors, including H2O2 and NMDA. Despite this
increased neuronal vulnerability, we did not observe ei-
ther nuclear or cytoplasmic TDP-43 aggregation. These
results suggesting that reduced levels of TDP-43 in the
nucleus may be critical for cytoxicity are consistent with
evidence reviewed by Z.S. Xu in a recent paper [28].
These results are also consistent with those of Barmada
et al. who recently established a TDP-43 proteinopathy
model by transfecting a mutant form of TDP-43 in rat
primary cortical neurons. They observed that their mu-
tant TDP-43 is translocated from nucleus to cytoplasm
and observed increased cell death. However, they found
no aggregation or inclusions in their neurons [29]. Re-
cent evidence from transgenic mice has also beenreported and appears consistent with this idea. Expres-
sion of a mutant TDP-43 plasmid induced neuron death
and degeneration, but did not lead to cytoplasmic inclu-
sions [30]. Moreover, some studies with other proteins
have shown that aggregation may even serve a protect-
ive role. In Huntington’s disease, for instance, mutant
Huntington protein (mHtt) is toxic when it is soluble
[31,32]. Overexpression of mHtt in HEK293 cells caused
aggregation but had no effect on cell survival. However,
when mHtt was overexpressed with the small guanine
nucleotide-binding protein Rhes, it showed decreased
aggregation but increased cell death [33]. Together
those results are leading to the view that protein aggre-
gation is not an obligatory factor leading to cytotoxicity.
Protein aggregation has been observed in a number of
neurodegenerative diseases. While aggregation is gener-
ally to be associated with cytotoxicity, it can also be a
phenomenon associated with excessive ER stress, which
is caused by an unusually large amount of misfolded
proteins in the cell [34-38]. In fact, it is now clear that
overexpression of wild-type TDP-43 can also cause ag-
gregation and cytotoxicity as observed by us (Figure 6)
and others [16,39]. Expression of large amounts of wild-
type TDP-43 might cause an ER stress response and
then initiate cell death. By reducing the protein-protein
interaction that leads to aggregation, the present study,
Figure 4 Synthetic peptides can inhibit TDP-43 aggregation. A: Peptide B, C and B + C combined were able to inhibit aggregation more
efficiently than the other three peptide candidates. B: Peptide B, C and the B + C mixture inhibit aggregation in a concentration-dependent
manner (*, p < 0.05; **, p < 0.01, one-way ANOVA). The data shown are from an experiment with three replicates.
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Figure 5 Synthetic peptides decreased arsenite induced TDP-43 aggregation. Insoluble and soluble TDP-43 levels were quantified under
different conditions (basal, arsenite, arsenite + Peptide ABCDE, arsenite + Scrambled peptide) (*, p < 0.05; **, p < 0.01, one-way ANOVA). The data
shown are from an experiment with three replicates.
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the phenotype of TDP-43 aggregation from that of
cytotoxicity. It also provides insights into the mechan-
ism of TDP-43 toxicity in FTD and ALS. Our study suf-
fers from the limitation that our experiments were
performed in a HeLa cell model. FTLD and ALS are
diseases of neurons, and moreover of specific popula-















Figure 6 Assessment of cell viability using the MTT assay. Cells were t
B and C were unable to prevent cell death. Cell viability was normalized to
data shown are from an experiment with three replicates.and replicated in selected populations of cultured neu-
rons. In addition, further studies in transgenic mice will
be needed to determine whether our peptides can also
reduce TDP-43 aggregation in vivo. Furthermore, the
same approach as the one taken here may be used to
study the role of aggregation of other proteins, e.g.
Huntingtin, α-synuclein, β-amyloid, in other neurode-
generative diseases.ransfected with either wild type or mutated TDP-43 plasmids. Peptides













Figure 7 Synthetic peptides did not rescue arsenite induced cell toxicity. Cell viability was assessed using the MTT assay and normalized to
the basal condition (*, p < 0.05; **, p < 0.01, one-way ANOVA). The data shown are from an experiment with three replicates.
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In this study, we are the first group to identify the
regions in TDP-43 protein that involve in its self-
aggregation. Peptides derived from those regions can
effectively reduce the aggregation in cells transfected
with an aggregation prone mutant TDP-43 or treated
with arsenite. We then showed that reducing TDP-43Figure 8 Schematic flowchart of the cell death studies. Cell death was
with GFP and the wild type TDP-43 or mutated TDP-43 plasmid. About 100
and C, the amount of cells with aggregation decreased. However, despite
non-aggregated cells. This suggests that the peptides can inhibit aggregat
death in untransfected cells suggests the peptides are not toxic to cells.aggregation did not protect cells from cell death
caused by either the expression of mutant TDP-43 or
arsentie treatment. Thus, our study is the first to
separate aggregation of TDP-43 from other factors
involved in TDP-43 proteinopathy and demonstrate
that TPD-43 aggregation may not be the cause of
cytotoxicity.identified using the TUNEL assay in HeLa cells. Cells were transfected
0 cells of each sample were counted. After treatment with Peptide B
the reduction in aggregation, increased cell death was observed in the
ion but not cell death. In addition, the very low percentage of cell
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Protein array
The peptides were synthesized on derivatized cellulose-
based membranes (Intavis AG, Köln, Germany) by the
UBC Peptide Synthesis facility using a previously de-
scribed protocol [40]. The peptide scans were performed
by synthesizing overlapping 12 or 14-mer peptides span-
ning the entire 414 amino acid sequence of TDP-43 with
a frame shift of 2 amino acids per spot. The TDP-43 pro-
tein was purified from E. coil overexpressing the human
TDP-43 gene. Membranes were blocked with 5% sucrose
and 4% nonfat dry milk in Tris-buffered Saline Tween-20
(TBST) for 4 h and then incubated with TDP-43 protein
(3–10 μg/ml) or peptides overnight at 4°C. Then mem-
branes were incubated with rabbit polyclonal TDP-43
antibody (1:5000; Protein Tech Group, Chicago, IL) over-
night at 4°C. After washing three times for 15 min, mem-
branes were incubated with donkey anti-goat conjugated
with donkey anti-rabbit IgG conjugated with horseradish
peroxidase (1: 5000; R&D Systems, Minneapolis, MN) for
3 h at room temperature. Membranes were then washed
three times for 15 min and protein interaction was visual-
ized with an enhanced chemiluminescence reaction assay
(PerkinElmer Life Sciences).
Cell-penetrating peptide synthesis
Cell-penetrating peptides consisting of the truncated
TAT domain at the N-terminal were synthesized by GL
biochem Ltd. (Shanghai) and purified by HPLC. TAT,
the trans-acting activator of transcription of the human
immunodeficiency virus (HIV-1), has been used as an ef-
ficient way of delivering proteins or peptides into cells
[41]. The resulting peptides were more than 90% pure
and verified by mass spectrometry. All the peptides were
first dissolved in DMSO and further diluted in water be-
fore usage.
Blocking assay of TDP-43 interaction with the membrane
Membranes were incubated with the mixture of TDP-43
protein (5 μg/ml) and/or single synthetic peptides
(100 μg/ml) overnight at 4°C. Then the membranes were
incubated sequentially with primary antibody and sec-
ondary antibody and washed with TBST. The protein
interaction was visualized using an enhanced chemilu-
minescence reaction assay (PerkinElmer Life Sciences).
Optical densities of each peptide array were measured
using NIH ImageJ software.
Cell cultures, transfection and treatment
HeLa cells were obtained from the American Type Cul-
ture Collection (ATCC) and grown in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma Chemical Co., St. Louis,
MO) supplemented with 10% fetal bovine serum (Gibco-
BRL, Grand Island, NY) and 1% antibiotics (Gibco-BRL,Grand Island, NY). Cultures were maintained at 37°C in a
humidified incubator (NuAir, Plymouth, MN) with 5%
CO2. Wild type TDP-43 plasmid and mutant TDP-43
plasmid lacking residues 187–192 were obtained from
Dr. Nonaka and Dr. Arai. The plasmids were transfected
into the HeLa cells using the Lipofectamine 2000 system
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions. After incubating the cells with the
transfection mixture for 5 hours, the medium was re-
placed with fresh DMEM (10% fetal bovine serum) with
2.5–20 μM synthetic peptides. After 24 hours, the medium
was replaced with fresh peptides. The cells were returned
to the incubator for an additional 24 hours before study.
For studies using arsenite, arsenite (Fisher scientific CO.,
Pittsburg, PA) was added to the cell culture medium to a
final concentration of 0.5 μM with or without the presence
of synthetic peptides. The cells were then returned to the
incubator for 4 hours before harvesting and analysis.
Immunofluorescence studies
Cells were fixed with pre-warmed 4% Paraformaldehyde
(PFA; Sigma, Saint Louis, MO) containing 4% sucrose
(Sigma, Saint Louis, MO) in PBS for 10 minutes at room
temperature and permeabilized with 0.1% Trition X-100
(Sigma, Saint Louis, MO) in PBS for 2–3 minutes at
room temperature. Then the reaction was blocked with
10% Bovine serum albumin (BSA; Invitrogen, Carlsbad,
CA) in PBS for 1 hour at room temperature and incu-
bated with a primary antibody against TDP-43 (1:150;
ProteinTech, Chicago, IL) overnight at 4°C. Reactions
were visualized with anti-rabbit antibody conjugated
with Alexa 488 (Invitrogen, Carlsbad, CA). Cell nuclei
were labeled with DAPI (1:10000; Invitrogen, Carlsbad,
CA) for 2–3 minutes at room temperature. Images were
obtained with an Olympus Fluoview FV1000 Confocal
scanning microscope.
MTT assay for cell viability
The viability of cultured cells was assessed using
the MTT assay. MTT (3-(4,5-dimethylthiazol-yl)-2,5-
diphenyltetrazolium bromide) (Sigma, Saint Louis,
MO) was added to each well (20 μl, 5 mg/ml). After
4 h incubation, cells were lysed overnight. The optical
density of test and control samples was measured at
590 nm absorbance with a reference filter of 750 nm
using a “uQuant” microplate spectrophotometer (Bio-
Tek Instruments, USA). The absorbance was translated
into cell viability ratios for comparison: cell viability
ratio = (test sample absorbance/control sample absorb-
ance) × 100%.
TUNEL assay for cell viability
Deoxynucleotidyl-transferase-mediated dUTP nick end-
labeling (TUNEL) staining was performed using an in
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Cells were seeded on poly-D-lysine coated cover slips at
a density of 2.5 × 104 cells per well in 24 well plate. After
treatment, cells were fixed and stained with anti-TDP-43
(1:150; ProteinTech, Chicago, IL), anti-GFP (1:1000;
Invitrogen, Carlsbad, CA), Alexa 647 anti-rabbit (1:1000;
Invitrogen, Carlsbad, CA) and Alexa 488 anti-chicken
(1:1000; Invitrogen, Carlsbad, CA). The enzyme solution
(terminal transferase) and label solution were mixed in a
volume ratio of 1:9 to obtain the TUNEL reaction mix-
ture. The cells were incubated with the 50 μl TUNEL re-
action mixture at 37°C for 1 hour and then washed three
times with PBS. Then the cover slips were mounted on
glass slides with antifade reagent (Invitrogen, Carlsbad,
CA). Images were obtained with an Olympus Fluoview
FV1000 Confocal scanning microscope.
Biochemical fractionation
To examine the effect of arsenite on solubility of endogen-
ous TDP-43, preparation of soluble/insoluble protein were
performed. HeLa cells were washed twice with cold PBS,
lysed in cold lysis buffer (PBS with 1% Triton X-100,
10 μg/ml aprotinin, 0.5 mM PMSF). Cell lysates were ro-
tated for 15 min and then centrifuged at 55,000 rpm for
15 min at 4°C. The supernatants were collected as soluble
proteins. To prevent contamination caused by carrying
over, the pellets were re-centrifuged at 55,000 rpm for
15 min at 4°C and washed once with lysis buffer. Then the
pellets were lysed in PBS with 1% SDS and sonicated. The
supernatants were collected as insoluble protein. Soluble
and insoluble proteins were analyzed by immunoblotting.
Immunoblotting
Protein concentrations of cell lysate and medium were
measured using a standard BCA assay (Bio-Rad) as per
the manufacturer’s instructions. Proteins were separated
in SDS–PAGE (10%) and transferred to nitrocellulose
membranes (Bio-Rad) at 4°C. Membranes were blocked
with 5% nonfat dry milk in TBST for 1 hour, then incu-
bated in 5% nonfat dry milk/TBST overnight at 4°C with
antibodies for TDP-43 or β-actin (rabbit IgG, 1:1000;
Cell Signaling, Danvers, MA). After washing with TBST,
membranes were incubated with anti-rabbit secondary
antibody conjugated with horseradish peroxidase for
1 hour at room temperature. Blots were developed using
an enhanced chemiluminescence reaction assay.
Statistical analysis
All data were expressed as mean ± SD and analyzed by
one-way ANOVA. A value of p < 0.05 was considered
statistically significant.
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